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Tissue-specific radiopharmaceuticals having promise as diagnostic and therapeutic 
targeting vectors for human cancers is of significant interest.  In recent years, our 
group and many others have focused upon design and development of targeting 
vectors having high selectivity and affinity for the gastrin-releasing peptide receptor 
(GRPr). GRP receptors are known to be over-expressed on a variety of malignancies 
including breast, lung, pancreatic, and prostate cancers. Bombesin (BBN), an 
amphibian analogue of mammalian GRP, has demonstrated the ability to bind with 
high affinity and specificity to the GRP receptor.  In this study, we report the 
synthesis of the bifunctional chelating agent (BFCA) 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) and conjugation to the biologically active BBN targeting 
vector. Bombesin conjugates were derived of the form, NOTA-X-BBN (X = GGG, 
SSS, ßAla, 5Ava, and 8Aoc).  The unligated BBN [7-14] peptides with spacer groups 
were synthesized by solid-phase peptide synthesis (SPPS) and purified by reverse 
phase-high performance liquid chromatography (RP-HPLC). NOTA chelator was 
conjugated to the N-terminal primary amine of BBN manually. The final NOTA-X-
BBN derivatives were purified by RP-HPLC and their chemical constitution verified.  
[64Cu-NOTA-X-BBN]-conjugates were prepared by addition of 64CuCl2 to a buffered 
solution containing the conjugate followed by purification via RP-HPLC.  In vivo 
studies of [64Cu-NOTA-8-Aoc-BBN]-conjugates in normal CF-1 mice showed 
receptor-specific uptake in normal pancreatic tissue, an organ known to express the 
GRPr in very high numbers. Furthermore, studies in human-prostate tumor-bearing 
mice have demonstrated the ability of [64Cu-NOTA-8-Aoc-BBN] to undergo 
receptor-specific tumor uptake. Diagnostic positron emission tomography (PET) 
imaging using this conjugate was successful in resolving xenografted tumors in a 
mouse model. Both normal and tumor-bearing mice exhibited low liver 
accumulation of Cu-64, a known complication of 64Cu-containing 
radiopharmaceuticals. Further studies are needed to verify the efficacy of [64Cu-
NOTA-8-Aoc-BBN] to target other human malignancies. 
 
